Pharmaceutical diagnostics operations occupy a strategically vital position in modern precision medicine. For pharma CEOs, managing diagnostics operations means bridging the development of companion diagnostics with therapeutic programs, building laboratory partnerships that support clinical trials and commercial testing, constructing reimbursement strategies for novel diagnostic products, and negotiating co-commercialization agreements with in vitro diagnostic partners. Each of these functions demands operational depth that many pharma organizations build too late, creating commercial delays and missed market opportunities.
The Strategic Importance of Diagnostics Operations
The rise of precision oncology, genomic medicine, and targeted therapies has made diagnostics operations a core pharma competency rather than an ancillary function. When a therapy’s approval is linked to a companion diagnostic, the drug cannot be prescribed without a functioning, commercially available, and reimbursed test. The diagnostic is not a support product; it is a prerequisite for therapy utilization.
Pharma CEOs who treat companion diagnostics as a regulatory checkbox rather than an operational priority consistently underperform in targeted therapy launches. The operational failures are predictable: companion diagnostic approval lags behind drug approval, leaving oncologists unable to identify eligible patients; laboratory testing infrastructure for a novel biomarker is not in place at launch; reimbursement coverage for the companion test is incomplete, creating patient access barriers; and co-commercialization partner relationships are not formalized in time to enable coordinated launch activities.
Avoiding these failures requires building diagnostics operations as a parallel and integrated function alongside therapeutic development and commercialization, not as a downstream afterthought.
Companion Diagnostic Development Operations
Companion diagnostic development requires coordination between pharmaceutical development teams and in vitro diagnostic development partners across a timeline that typically spans five to eight years from biomarker identification to regulatory approval.
The operational foundation is a formal co-development agreement between the pharma company and the IVD partner. This agreement defines the division of development responsibilities, the sharing of clinical specimens from therapeutic trials for assay development and validation, intellectual property ownership and licensing terms, regulatory submission coordination, and the commercial relationship post-approval. Negotiating this agreement early in development, ideally at the time of biomarker hypothesis, prevents costly disputes and misalignments as the program matures.
Biomarker strategy is an upstream operational decision with long downstream implications. Choosing a biomarker that can be measured with existing laboratory infrastructure reduces the time and cost to build testing capacity but may not be the most clinically meaningful patient selection marker. Novel biomarkers that require new measurement technologies may better identify the patient population that benefits from the therapy but demand significant laboratory build-out before commercial availability.
Clinical specimen logistics are a specific operational challenge in companion diagnostic development. IVD partners need access to tumor samples, blood specimens, or other biological materials from therapeutic clinical trial participants to develop and validate the companion diagnostic assay. Building specimen collection, processing, storage, and transfer protocols into the clinical trial infrastructure from the start, with appropriate patient consent and chain of custody documentation, avoids the specimen access bottlenecks that commonly delay companion diagnostic programs.
FDA regulatory coordination for companion diagnostics requires parallel engagement with the Center for Drug Evaluation and Research, which reviews the drug, and the Center for Devices and Radiological Health, which reviews the companion diagnostic. Organizing joint meetings with both centers early in development to align on acceptable analytical and clinical validation standards, acceptable specimen types, and labeling language establishes a shared regulatory roadmap that reduces surprises at the submission stage.
The pharma business checklist outlines the operational milestones pharma CEOs should track across diagnostic and therapeutic programs. For operations specific to partnerships and licensing arrangements, the partnerships and licensing ops resource provides detailed frameworks.
Laboratory Partnership Operations
Commercial companion diagnostic testing depends on laboratory infrastructure. Building the laboratory network capable of running a companion diagnostic at commercial scale is an operational initiative that must begin well before regulatory approval.
Laboratory partner types include national reference laboratories such as Quest Diagnostics and Labcorp, hospital-based laboratory systems, specialized oncology testing laboratories, and pathology group practices. Each partner type offers different geographic reach, test menu positioning, payer contracting leverage, and turnaround time capabilities.
National reference laboratories offer national scale and established payer relationships, making them attractive for broad population testing. However, onboarding a new test at a national reference laboratory involves complex technology transfer, reagent supply chain establishment, staff training, and quality system validation, all of which take time and require dedicated operational project management.
Specialized oncology laboratories, including Foundation Medicine, Guardant Health, and similar entities, are already positioned in the oncology testing market and have existing relationships with oncologists. Partnering with these laboratories for companion diagnostic testing leverages their existing commercial infrastructure but requires clear contractual terms on exclusivity, test pricing, reporting standards, and data sharing.
The operational mechanics of laboratory onboarding include technology transfer of the assay methodology, training of laboratory staff, proficiency testing programs to validate performance across laboratory sites, and quality oversight mechanisms that allow the pharma company and IVD partner to monitor post-market assay performance. Building a laboratory network management function with dedicated staff who maintain relationships with laboratory partners and monitor testing operations is an operational investment justified by its impact on test availability and quality.
Specimen logistics from community oncology practices, academic cancer centers, and hospital pathology departments to testing laboratories represent a significant operational coordination challenge. Ensuring that oncologists and pathology departments have the specimen collection supplies, shipping materials, requisition processes, and electronic ordering integration needed to submit specimens easily reduces pre-analytical barriers to testing.
Reimbursement Strategy Operations
Reimbursement is the access gateway for companion diagnostics. Without adequate coverage and payment, patients either do not receive testing or face out-of-pocket costs that deter access. Building reimbursement operations for a novel companion diagnostic requires engagement across Medicare, Medicaid, and commercial payer channels simultaneously.
Medicare coverage for molecular diagnostic tests is determined primarily through the Molecular Diagnostic Services program and, where applicable, local coverage determinations issued by Medicare Administrative Contractors. Obtaining a specific Current Procedural Terminology code for the companion diagnostic is typically the first step, followed by seeking coverage through payer policies linked to FDA-approved labeling.
The MAAA (Multianalyte Assays with Algorithmic Analyses) and PLA (Proprietary Laboratory Analysis) code pathways provide mechanisms for companion diagnostics with novel analytical characteristics to obtain specific coding and payment. Navigating these pathways requires regulatory and reimbursement expertise that many pharma companies lack in-house and must source through specialized consultants or dedicated market access staff.
Health economics and outcomes research data is the foundation of payer coverage arguments. Demonstrating that identifying the biomarker-positive patient population through testing improves clinical outcomes, reduces inappropriate therapy use, and saves costs compared to empiric treatment provides the value proposition that payers need to justify coverage policies. Building this evidence base, typically through published analyses of clinical trial data and real-world evidence studies, should begin during the development phase and continue post-launch.
Commercial payer coverage is typically more fragmented and variable than Medicare coverage. Major commercial payers each make independent coverage determinations, often influenced by emerging evidence, clinical guidelines from organizations such as NCCN and ASCO, and FDA labeling. Building a payer engagement program that proactively shares clinical evidence with medical directors at major commercial payers, tracks coverage policy status across payers, and escalates coverage gaps for appeal or re-engagement is an ongoing operational function.
Co-Commercialization Agreement Operations
Co-commercialization agreements between pharma companies and IVD partners create shared commercial responsibility for companion diagnostic testing volume. These agreements are operationally complex and require active management throughout the commercial lifecycle.
The commercial relationship typically involves the pharma company’s oncology sales force engaging prescribers with information about the therapeutic product and the companion diagnostic testing requirement, while the IVD partner’s laboratory sales force focuses on ensuring that laboratory infrastructure and test availability are in place. Coordinating these two commercial functions without creating duplicative or conflicting customer touchpoints requires clear role definition, shared account planning, and joint sales leadership alignment.
Shared promotional materials must comply with FDA regulations governing both drug and device promotion. Developing compliant materials that address both the therapy and the companion diagnostic requires coordination between the pharma regulatory and medical affairs teams and the IVD partner’s regulatory function. Building a joint promotional materials review process with agreed timelines and approval protocols prevents launch delays caused by promotional review gridlock.
Revenue sharing and financial settlement between co-commercialization partners requires transparent reporting of test volumes, payment collections, and shared expense allocations. Building reconciliation processes that both parties trust, supported by agreed data sources and audit rights, prevents financial disputes that can damage the partnership relationship.
According to McKinsey research on precision medicine commercialization, companion diagnostic launch readiness, specifically having laboratory network coverage, reimbursement coverage, and co-commercialization alignment in place at drug approval, is the single most significant predictor of first-year targeted therapy uptake.
Diagnostics operations demand from the pharma CEO the same rigor, cross-functional coordination, and long-term planning discipline that characterizes successful therapeutic development. Those who build robust companion diagnostic development, laboratory partnership, reimbursement strategy, and co-commercialization operations position their organizations for durable precision medicine leadership.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.